Tech Company Financing Transactions
DermBiont Funding Round
On 6/20/2019, DermBiont received $8 million in Series A investment from Toba Capital, Viking Global Investors and Zola.
Transaction Overview
Company Name
Announced On
6/20/2019
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
Toba Capital (Lead Investor)
Viking Global Investors (Lead Investor)
Zola (Lead Investor)
private investors (Mark de Souza)
Proceeds Purpose
The financing proceeds will be used to fund ongoing clinical trials and discovery.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Kneeland St. 14th Floor
Boston, MA 02118
USA
Boston, MA 02118
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
DermBiont develops skin microbiome therapeutics platform to treat and prevent skin diseases. DermBiont is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Karl Beutner
Chief Financial Officer
Max Dawson
Chief Medical Officer
Shilpa Goel
Chief Scientific Officer
Robert Brucker
VP - Bus. Development
Nick Eliovits
VP - Operations
Sanjay Jain
VP - Operations
Deryck Wade
VP - R & D
Xuecheng Zhang
Browse more venture capital transactions:
Prev: 6/20/2019: Expel venture capital transaction
Next: 6/20/2019: Mattermost venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record tech company VC transactions. VC transactions reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs